Zams

Researchers are evaluating trastuzumab deruxtecan T-DXd as a treatment for adult patients with advanced HER2-positive gastric or gastroesophageal junction GEJ adenocarcinoma who have previously received a trastuzumab-based regimen. This study aims to assess the real-world effectiveness of T-DXd, patient characteristics, treatment patterns, and safety in this population. It also includes data collection on patients receiving conventional therapies for exploratory comparison. This is a non-interventional observational study where patients receive T-DXd or conventional therapies as part of routine clinical care according to approved guidelines SmPC. No investigational drugs are given. The study tracks patients starting T-DXd as a second-line or later treatment and collects data on other therapies such as chemotherapy and immunotherapy used in clinical practice. Participants will be followed for up to approximately 2 years from baseline to monitor outcomes including time to next treatment, changes in treatment, physician-reported safety events, use of prophylactic treatments, and quality of life using validated questionnaires. Data on physician visits, treatment discontinuation, and safety events will also be collected to understand treatment tolerability and patient experience in a real-world setting.

Metastatic colorectal cancer mCRC is a serious condition with limited treatment options after multiple therapies. Researchers are gathering detailed information on patients with mCRC who have already had at least two lines of systemic therapy. This registry aims to understand how these patients are treated and how they fare over time, collecting data from multiple cancer centers in Austria to better evaluate treatment patterns and outcomes. The study involves collecting existing medical data from patient charts, including treatment histories, test results, and imaging studies. Tumor tissue samples from deceased patients will be stored in a central biobank, and additional biological samples may be requested for specific research questions. No new diagnostic or treatment procedures are required beyond routine care. Data collection will continue until patient death or loss to follow-up. Participants involvement includes providing consent for their routine medical data to be recorded in the registry. Researchers will monitor overall survival, progression-free survival, response rates, and potential predictive biomarkers over a period of up to 10 years. Patient confidentiality is maintained by assigning unique identifiers, and no extra visits or therapies are needed beyond usual care.

Researchers are collecting and analyzing real-world data on treatment patterns, clinical outcomes, and side effects in adults with advanced pancreatic ductal adenocarcinoma PDAC in Austria. This observational study focuses on patients with locally advanced inoperable or metastatic PDAC who are receiving first-line chemotherapy as part of their palliative care. The study includes 1500 adult patients undergoing first-line chemotherapy with platinum- or gemcitabine-based regimens, including nal-Irinotecan5-FULeukovorin for those with prior neoadjuvant therapy. Data will be collected on the use and impact of approved chemotherapeutic agents from second-line treatment and on various treatment patterns, molecular testing, and outcomes over a 24-month period. Participants will be monitored for clinical outcomes, treatment efficacy, and side effects such as neuropathy, anemia, nausea, and skin toxicity. The study also tracks treatment behaviors after disease progression, the use of tumor resection or metastasectomy, and the influence of factors like diabetes or genetic mutations. Researchers will analyze data to identify predictors of treatment success and adverse events, with the primary outcome focusing on the proportion of patients receiving second-line palliative therapy after progression on first-line treatment.

Researchers are evaluating the use of Sonodyn, an investigational handheld medical device, for adults suffering from therapy-resistant myofascial pain syndrome causing low back pain, tension headache, or neck pain. This condition is a common cause of muscle pain and dysfunction, characterized by trigger points in muscles. The study is a randomized, double-blind, sham-controlled trial conducted at multiple sites in Austria and Switzerland to assess the devices impact on pain levels. The study compares active Sonodyn therapy, which delivers low-energy ultrasound, electrical, and magnetic stimulation to targeted trigger points, with a sham device that looks identical but does not deliver any stimulation. Patients undergo treatment for three weeks, activating their assigned device three times daily for 10 minutes each session. The trial includes a one-week screening phase before treatment and an eight-week follow-up period after treatment, totaling 12 weeks of participation. Participants report their average and maximum pain intensity twice daily using a Numeric Rating Scale throughout screening, treatment, and follow-up periods. They also track the use of any rescue medication. Researchers will measure pain changes as the primary outcome and assess additional factors such as medication use, quality of sleep, and quality of life. The study monitors compliance and safety while comparing results between active therapy and sham control groups.